HIV AIDS News

Promising to take “aggressive action” to end HIV in the U.S., President Joe Biden on Worlds Aids Day on Wednesday announced a 3-year roadmap to help reduce new HIV transmissions in the U.S. by 90% by 2030. And he did so by being the first U.S. president to link systemic racism and other discrimination directly to the prolonged HIV epidemic.

Officials say new infections have declined among white gay and bisexual men over the past decade, but Black and Hispanic counterparts did not see that advance.

The woman is the second known person to have potentially cleared HIV infection naturally.

Findings could help people with HIV keep the virus in remission without taking medications that can have long-term side effects,

The Black women members of the President’s Advisory Council on HIV/AIDS (PACHA) are far from the first to bring their expertise to the HIV epidemic, as Daniel Royles, PhD, an assistant professor of history at Florida International University, learned when he started working on a history of AIDS activism in Philadelphia.

In August, when Assistant Secretary for Health Rachel Levine swore in eight new members to the President’s Advisory Council on HIV/AIDS (PACHA), the U.S.’s most influential policy sounding board of people living with HIV, their clinicians, drug makers, and public health leaders, she was presiding over the largest group of HIV advisers since former President Donald Trump fired the entire membership in June 2017.

A new study warns people with HIV have an increased risk of sudden cardiac death, especially if the virus isn't well-controlled.

An mRNA vaccine targeting HIV will soon enter phase I clinical study.

Johnson & Johnson's clinical trial of an experimental HIV vaccine has failed.

For years, men who have sex with men have faced extra restrictions if they tried to donate blood. A study now underway may lead to a shift in policy.

Nearly all health insurers must cover the entire cost of HIV prevention treatments. The two approved pre-exposure prophylaxis (PrEP) drugs are Truvada and Descovy.

Autopsies of those with HIV found scarring of the heart muscle -- called fibrosis -- which may explain why sudden cardiac death is more likely.

Despite significant advances in HIV research, prevention, and treatment, HIV is still criminalized both in the U.S. and abroad. Is this the ultimate challenge to ending the epidemic?

New research shows that having HIV or AIDS increases a person's risk of catching and dying from COVID-19.

New research raises questions about one drug featured in many ART recipes: tenofovir alafenamide, also known as TAF.

A preliminary trial suggests a vaginal ring that slowly releases an antiviral medication could protect women against HIV for up to three months.

This could give some adult patients the option of receiving an injection once a month instead of taking a daily pill.

The daily drug regimen known as PrEP is a nearly foolproof way to prevent HIV infection. But a new study suggests that many high-risk Americans may be giving the medication a pass because of cost.

A single injection of the experimental drug, called lenacapavir, was able to lower blood levels of HIV in a small group of patients. And it was capable of maintaining active levels in the blood for more than six months.

HIV may not be the death sentence it was 20 or 30 years ago, but people who are HIV-positive still face much shorter lives than other adults -- even if they're treated with medications that make the virus undetectable.

HIV can reside in brain cells and spread the AIDS-causing virus to the body, a new study in mice indicates.

Kramer struggled with illness for much of his adult life, including infection with the AIDS-causing HIV virus. He also had a liver disease and required a liver transplant.

Researchers have reformulated an HIV medication into a version they hope can eventually be taken as infrequently as once a year.

The study authors said that their analysis found that an expensive new branded formulation of PrEP -- touted as being safer by the company that makes  it -- would in reality be no better than cheaper generics.

Adam Castillejo was known until recently only as the "London patient." Now, after surviving years of grueling treatments, he says he sees himself as an "ambassador of hope" for others.